You are hereSeptember 21, 2021
MSC-EVs for Neurodegenerative Disease
Treating neurological disorders remains a challenge due to the implication of multifactorial, complex etiologies. In recent years, the therapeutic benefits of the intranasal administration of extracellular vesicles isolated from mesenchymal stem cells (MSC-EVs) have gained attention. Extracellular vesicles retain the advantages of their parental cells, while intranasal administration provides a non-invasive method to bypass the blood-brain barrier and target specific pathological regions. In a recent STEM CELLS review article, researchers led by Daniel Offen (Tel Aviv University, Israel) summarize the current status of research into MSC-EVs administrated via the intranasal pathways and the potential of this promising therapeutic approach.